New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? (Q38089480)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Barbara Guinn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

V Boncheva

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

S A Bonney

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

S E Brooks

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

G O'Sullivan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

A Mirnezami

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

15 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

157-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/cgt.2013.5

26 February 2020

exact match

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Socio-economic factors and health care system characteristics related to cancer survival in the elderly. A population-based analysis in 16 European countries (ELDCARE project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

The global burden of cancer: priorities for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Global patterns of cancer incidence and mortality rates and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Adjuvant therapy for stage II colon cancer: an elephant in the living room?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Noninvasive molecular biomarkers for the detection of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer vaccines: moving beyond current paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Proteomics/genomics and signaling in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Serologic detection of diffuse large B-cell lymphoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Isolation and characterization of human lung cancer antigens by serological screening with autologous antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Autoantibody profiling for cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

The biology of cancer testis antigens: putative function, regulation and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/testis (CT) antigens: potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

New paths in human cancer serology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Serological analysis of human tumor antigens: molecular definition and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Gene cloning of immunogenic antigens overexpressed in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

SEREX identification of new tumor antigens linked to melanoma-associated retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Immunoscreening of the extracellular proteome of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Proteome serological determination of tumor-associated antigens in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Identification of tumor antigens in renal cell carcinoma by serological proteome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Highlights on the capacities of "Gel-based" proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Serological immune response to cancer testis antigens in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

High throughput proteomic strategies for identifying tumour-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Detection and characterization of cellular immune responses using peptide-MHC microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

CABYR, a novel calcium-binding tyrosine phosphorylation-regulated fibrous sheath protein involved in capacitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

CABYR is a novel cancer-testis antigen in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Characterization of two non-testis-specific CABYR variants that bind to GSK3beta with a proline-rich extensin-like domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Expression of the sperm fibrous sheath protein CABYR in human cancers and identification of α-enolase as an interacting partner of CABYR-a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Sperm associated antigen 9 (SPAG9): a new member of c-Jun NH2 -terminal kinase (JNK) interacting protein exclusively expressed in testis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

A new family of mouse genes homologous to the human MAGE genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

The SSX family of cancer-testis antigens as target proteins for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Identification and expansion of human colon-cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Preoperative carcinoembryonic antigen elevation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Proteolysis, proteasomes and antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Tregs and rethinking cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Regulatory T cells in colorectal cancer: from biology to prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon c

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

A majority of the cancer/testis antigens are intrinsically disordered proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Structural diversity in free and bound states of intrinsically disordered protein phosphatase 1 regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Protein folding and the order/disorder paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Rate constants and mechanisms of intrinsically disordered proteins binding to structured targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Uncoupled binding and folding of immune signaling-related intrinsically disordered proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Intrinsic disorder: signaling via highly specific but short-lived association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

21 January 2018

Evolution and disorder

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Protein disorder in the human diseasome: unfoldomics of human genetic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

Expression of cancer/testis (CT) antigens in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

The prognostic significance of direct extension of carcinoma of the colon and rectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

The expression and effects the CABYR-c transcript of CABYR gene in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.5

7 January 2021

Identifiers

DOI

10.1038/CGT.2013.5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23492821%20AND%20SRC:MED&resulttype=core&format=json